ORR up to 85.4%! Cindilli supretic r/r cHL-related research long-term follow-up data published
-
Last Update: 2020-06-17
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The ORIENT-1 study, presented at ASCO's annual meeting, is a multicenter, single-arm, ii-phase study that assesses the efficacy and safety of Cindilli sepsa in r/r cHLParticipants received 200 mg of Sindilme treatment every 3 weeks until the disease progressedThe study involved a total of 96 r/r cHL subjects, with the main clinical study endpoint being the Objective Mitigation Rate (ORR) assessed by the Independent Imaging Assessment Board (IRRC) and the secondary endpoint as the Full Mitigation Rate (CRR)as at 30 September 2019, the ORR for the ORIENT-1 study was 85.4% (82/96) and the CRR was 42.7% (41/96).
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
